Form 8-K NEKTAR THERAPEUTICS For: Sep 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
Nektar Therapeutics (NKTR) Sees Early Weakness
September 27, 2016 9:50 AM EDTNektar Therapeutics (NASDAQ: NKTR) is under heavy pressure this morning. Shares are down 8.6% on volume that is running 49x normal.
This morning, Bristol-Myers Squibb Company (NYSE: BMY) and Nektar Therapeutics... More
Nektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration
September 27, 2016 7:50 AM EDTNektar Therapeutics (Nasdaq: NKTR) disclosed the following in a U.S. SEC filing on Tuesday:
Item 1.01 Entry into a Material Definitive Agreement.
On September 21, 2016, Nektar Therapeutics, a Delaware corporation (Nektar), entered into a Clinical Trial Collaboration Agreement (the Agreement) with Bristol-Myers Squibb Company, a Delaware corporation (BMS), pursuant to which Nektar and BMS will collaborate to conduct Phase 1/2 clinical trials evaluating Nektars IL-2-based CD122-biased agonist, known as NKTR-214, and BMSs human monoclonal antibody that binds PD-1, known as Nivolumab, as a potential combination treatment regimen in five tumor types... More
